Santosh Kakad, AGM – Sales and Marketing, Nitika Pharmaceutical Specialties

In this video:
Santosh Kakad, AGM – Sales and Marketing, Nitika Pharmaceutical Specialties

Key Takeaway:
Nitrosamine levels in low-nitrite formulations remained under control even for high-risk products. Supplier selection of filler excipients, such as MCC and lactose, and the replacement of critical excipients, such as crospovidone, are obvious nitrosamine risk-mitigation strategies